BASKING RIDGE, N.J., May 14 /PRNewswire-FirstCall/ — Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (BULLETIN BOARD: MBTG) and P4 Healthcare LLC today announced a strategic alliance to deliver the Resurgex(R) line of high-quality nutrition products to cancer patients and oncology practices. The partnership brings together Millennium, a leading nutraceutical company and a pioneer in the field of specialized nutritional supplements, and P4 Healthcare, the world’s leading provider of customized solutions for Oncology Practices featuring premier patient educational resources and practice management tools.
The predecessor corporation to P4 Healthcare, International Oncology Network (ION), was founded in 1992. ION created a group purchasing organization (GPO) with the 100 largest oncology practices in the U.S. ION soon there-after quickly grew to 8 billion in sales and was acquired in 2003. P4 Healthcare evolved from the successful ION venture and was founded to continue catering to the needs of these same top 100 US private oncology practices.
P4 Healthcare LLC through its website, http://www.caring4cancer.com/ and patient guide, Caring4Cancer, reaches more than 1.2 million cancer patients annually. Many of the nation’s largest oncology practices now use the Caring4Cancer patient guide, a quarterly publication serving the interests and needs of cancer patients, survivors, and their families, as their primary patient education tool. With coverage of all aspects of cancer care — from diagnosis and treatment, to side effect management, nutrition, finances, sexuality, spirituality, and lifestyle matters — Caring4Cancer has quickly become a key patient education resource prescribed by doctors and nurses just as they prescribe medication or therapy.
Keeping to their core values of only offering the best in the area of information, products and services P4 has identified quality nutritional support, specifically Resurgex, as a key addition. “Offering our Oncology partners such a distinguished product as Resurgex(R) helps to solidify P4 and Caring4Cancer as the world’s leading provider of customized solutions for Oncology Practices,” comments P4 CEO Raj Mantena.
During phase one of the partnership, Millennium’s patented line of Resurgex(R) products will be promoted within the practices and made available online through P4 Healthcare’s website http://www.caring4cancer.com/. The website is a leading internet destination for cancer patients, caregivers and survivors that provides a wide range of trustworthy and valuable information and innovative health management tools reviewed by leading US oncologists. A growing online community creates an interactive venue for members to discuss issues impacting the oncology community from patients to caregivers.
Recently, approximately 40 of the top 100 practices were presented with the opportunity to make Resurgex(R) products available to their patients via caring4cancer.com. The response was overwhelming with over 95% of practices responding in the affirmative when asked if they would incorporate Resurgex into their practices. Resurgex(R) will be offered to patients throughout the entire course of their treatments and beyond in effort to yield more favorable treatment outcomes. “Proper nutrition is an important component in the therapeutic regimen for cancer. This alliance is a natural progression for Resurgex(R), given its leadership position in the oncology market,” said Jerry Swon, Sr., President of Millennium Biotechnologies Group, Inc.
Resurgex Select(R) has made significant inroads in the oncology marketplace and has been issued a U.S. Composition Patent for the proprietary formula, as well as a registered trademark. Resurgex Select(R) provides a superior source of high-quality calories as opposed to the corn oil and corn syrup-laden products that are found in the marketplace. As with the previous patent issued for Resurgex(R), this additional patent will protect the intellectual property of Millennium for the Resurgex(R) family of products.
About Millennium Biotechnologies, Inc.: Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company’s flagship products, Resurgex(R), Resurgex Plus(R), and Resurgex Select(R), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions.
Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (BULLETIN BOARD: MBTG) . For more information about Millennium Biotechnologies, please contact Jerry Swon, Chief Executive Officer, at [email protected] or call (908) 604-2500. For more information about the Resurgex(R) line of products visit http://www.resurgex.com/.
About P4 Healthcare, LLC: P4 Healthcare provides comprehensive, customized health care management solutions that increase practice efficiencies and enhance the quality of patient care. By partnering with the leading specialty therapeutic practices across the nation, P4 Healthcare connects physicians, patients, pharmaceutical companies, and payers to bring these practices new and innovative solutions to important business challenges-from practice efficiency and quality improvement programs to superior patient care solutions.
P4 Healthcare is a privately held company with vast experience partnering with oncology practices.
This release includes certain forward-looking information that is based upon management’s beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of our products and the factors identified in the Company’s 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
Millennium Biotechnologies, Inc.
CONTACT: Jerry Swon, Chief Executive Officer of MillenniumBiotechnologies, Inc., +1-908-604-2500, [email protected]
Web site: http://www.resurgex.com/http://www.caring4cancer.com/
Comments